

EuroValve
April 26-27, 2018




When to pursue rhythm control?

Nina Ajmone Marsan
MD, PhD, FESC

Leiden University Medical Center
The Netherlands

www.eurovalvecongress.com



EuroValve

April 26-27, 2018



Faculty disclosure


Nina Ajmone Marsan

I disclose the following financial relationships:

Advisory board of Philips Ultrasound


Paid speaker for Philips, GE

www.eurovalvecongress.com




When to pursue rhythm control?

- How to predict and prevent development of AF? Both before and after surgery for VHD
- Once episodes of AF have occurred, when and how should we pursue rhythm control?
- Is there a clinical/prognostic impact?





Mitral stenosis

- 30-40% of symptomatic pts develop AF
- Protection of SR is important: reduce risk of tromboembolism, mantain adequate cardiac output and exercise capacity, and reduce symptoms



1) Erbay et al, IJC 2005, 2) Krasuski et al, Am J Cardiol 2004








EuroValve
April 26-27, 2018

Organic Mitral Regurgitation

LA Volume





Le Tourneau et al, JACC 2010




EuroValve
April 26-27, 2018

Organic Mitral Regurgitation

LA reservoir strain



Debonnaire et al JASE 2013



Atrial Functional MR

Journal of the American College of Cardiology
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc.


Vol. 58, No. 14, 2011
ISSN 0735-1097/\$36.00
doi:10.1016/j.jacc.2011.06.032


Heart Rhythm Disorders

Evidence of Atrial Functional Mitral Regurgitation Due to Atrial Fibrillation

Reversal With Arrhythmia Control

Zachary M. Gertz, MD,* Amresh Raina, MD,* Laszlo Saghy, MD,† Erica S. Zado, PA-C,*
David J. Callans, MD,* Francis E. Marchlinski, MD,* Martin G. Keane, MD,* Frank E. Silvestry, MD*
Philadelphia, Pennsylvania; and Szeged, Hungary









EuroValve

April 26-27, 2018

Atrial Functional MR





Aortic stenosis

- AF in 30-40% of severe AS patients due to pressure overload of both LV and LA, presence of LVH, myocardial fibrosis and stiffness (diast dysfunction)








Fig. 1. Association of preoperative diastolic function with development of new-onset AF.






Aortic Stenosis



- Data from the simvastatin and ezetimibe in aortic stenosis study (SEAS):
 - 9% AF in asymptomatic pts with moderate AS
 - Longstanding AF in particular is associated with higher incidence of heart failure and stroke




EuroValve
April 26-27, 2018

Arrhythmia Burden in Elderly Patients With Severe Aortic Stenosis as Determined by Continuous Electrocardiographic Recording

Toward a Better Understanding of Arrhythmic Events After Transcatheter Aortic Valve Replacement


Marina Urena, MD; Salim Hayek, MD; Asim N. Cheema, MD; Vicenç Serra, MD; Ignacio J. Amat-Santos, MD; Luis Nombela-Franco, MD; Henrique B. Ribeiro, MD; Ricardo Allende, MD; Jean-Michel Paradis, MD; Eric Dumont, MD; Vinod H. Thourani, MD; Vasilis Babaliaros, MD; Jaume Francisco Pascual, MD; Carlos Cortés, MD; Bruno García del Blanco, MD; François Philippon, MD; Stamatios Lerakis, MD; Josep Rodés-Cabau, MD

24 hour ECG monitoring showed 16% new diagnosis of AF (mainly in pts with lower LVEF and higher CHADS-VASc score), associated with 18-fold higher incidence of cerebrovascular events (because of lack of oral anticoagulation therapy) and accounting for 1/3 of AF postTAVR (therefore probably not related to TAVR itself)



New onset AF (NOAF) after TAVR

- %




- Hepa

TAVR

d in


Amat-Santos et al JACC 2012


Tarantini et al, JACC Interventions 2016



New onset AF (NOAF) after TAVR


- Difference in association with outcome: 30 days and long-term incidence of stroke according to the initiation or not of oral anticoagulation and the different regimens
- Association with all-cause and CV mortality (mainly due to HF events), but also bleeding events
- Association with age, LA dimension and non-TF approach





AF after Cardiac Surgery

- **30% of patients undergoing cardiac surgery present sustained or recurrent AF (50% in CABG + valvular operation)**
- **Post-operative AF is associated with stroke, heart failure, infections and prolonged hospital stay duration , higher risk for readmission and death and overall increase of costs**



EuroValve
April 26-27, 2018

AF after Cardiac Surgery

The NEW ENGLAND
JOURNAL *of* MEDICINE


ESTABLISHED IN 1812

MAY 19, 2016

VOL. 374 NO. 20


Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery


A.M. Gillinov, E. Bagiella, A.J. Moskowitz, J.M. Raiten, M.A. Groh, M.E. Bowdish, G. Ailawadi, K.A. Kirkwood, L.P. Perrault, M.K. Parides, R.L. Smith II, J.A. Kern, G. Dussault, A.E. Hackmann, N.O. Jeffries, M.A. Miller, W.C. Taddei-Peters, E.A. Rose, R.D. Weisel, D.L. Williams, R.F. Mangusan, M. Argenziano, E.G. Moquete, K.L. O'Sullivan, M. Pellerin, K.J. Shah, J.S. Gammie, M.L. Mayer, P. Voisine, A.C. Gelijns, P.T. O'Gara, and M.J. Mack, for the CTSN*



AF after Cardiac Surgery

- Current guidelines from the American Heart Association/American College of Cardiology/Heart Rhythm Society recommend achieving rate control with beta-blockers or non-dihydropyridine calcium-channel blockers
- Amiodarone and sotalol can be considered as prophylaxis for NOAF (1)
- A systematic review by Marik and Fromm showed that periprocedural administration of corticosteroids the development of NOAF by more than 50% (inflammation is proarrhythmic)





EuroValve


April 26-27, 2018



Contents lists available at [SciVerse ScienceDirect](http://www.sciencedirect.com)

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard



Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement

Jordi S. Dahl ^{a,*}, Lars Videbæk ^a, Mikael K. Poulsen ^a, Patricia A. Pellikka ^b, Karsten Veien ^a, Lars Ib Andersen ^c, Torben Haghfelt ^a, Jacob E. Møller ^d


^a Department of Cardiology, Odense University Hospital, Denmark


^b Division of Cardiovascular Diseases, Mayo Clinic Rochester, USA

^c Department of Thoracic Surgery, Odense University Hospital, Denmark

Inhibition of RAAS has been associated with reduced risk of AF due to reduction of pressure overload and atrial stretch, LVH, myocardial fibrosis, direct ion-channel modulation


Also in this study, LV and LA remodeling were signs related with development of post-operative AF







Surgical treatment of AF


- COX-MAZE III procedure (cryo-ablation, cut and sew..)
- 60% of pts undergoing cardiac surgery have AF left untreated
- Inconsistent results, better during MV surgery, difference in lesions and energy
- The SWEDMAF had increased risk of perioperative complications (Blomstrom-Lundqvist et al, Eur H J 2007)





Surgical treatment of AF





EuroValve
April 26–27, 2018

Surgical treatment of AF




European Heart Journal (2012) 33, 2644–2652
doi:10.1093/eurheartj/ehs290

FASTTRACK
ESC HOT LINE

Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study[†]


Petr Budera^{1*}, Zbyněk Straka¹, Pavel Osmančík¹, Tomáš Vaněk¹, Štěpán Jelínek¹, Jan Hlavička¹, Richard Fojt¹, Pavel Červinka², Michal Hulman³, Michal Šmíd⁴, Marek Malý⁵, and Petr Widimský¹


¹Department of Cardiac Surgery, University Hospital Brno, Brno, Czech Republic; ²Department of Cardiac Surgery, University Hospital Olomouc, Olomouc, Czech Republic; ³Department of Cardiac Surgery, University Hospital Pilsen, Pilsen, Czech Republic; ⁴Department of Cardiac Surgery, University Hospital Hradec Králové, Hradec Králové, Czech Republic; ⁵Department of Cardiac Surgery, University Hospital Plzeň, Plzeň, Czech Republic



Surgical treatment of AF

- Significant difference in maintaining SR but no impact on (long-term) mortality
- More evident at 1 year for the long-standing persistent AF
- Significant also only for MV surgery; CAD could be a risk factor for failure of ablation





Conclusions

- Monitor pts with VHD measuring also LA dimension/volume (and function) and consider performing Holter monitoring
- Lack of clinical trials comparing rate versus rhythm control specifically in VHD but AF is of prognostic value and represents an indication for surgery (MV)
- Consider adding MAZE to surgery for VHD
- Consider specific treatment to prevent NOAF after after surgery/percutaneous procedures; when NOAF occurs in principle rate and rhythm control are comparable options